Efficacy and safety of dapagliflozin in patients with CKD: real-world experience in 93 Italian renal clinics.

Background: Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are recommended for reducing the renal and cardiovascular risk in patients with chronic kidney disease (CKD) based on the positive results reported by clinical trials. However, real-world data on the efficacy and the safety of these drugs in CKD population followed in nephrology setting are lacking.

Methods: We report the effects of dapagliflozin in CKD patients by using data collected during a learning program in which 105 nephrologists added dapagliflozin (10 mg/day) to consecutive patients referred to their renal clinics.

Real-time wastewater quality monitoring by fluorescence sensors: Validation for COD and CEC monitoring and implication for carbon footprint reduction.

This study investigated the applicability of a protein-like fluorescence sensor for wastewater quality monitoring. Several wastewater matrices, including raw, primary, secondary and tertiary effluents from three different wastewater treatment plants were used. Furthermore, the sensor was tested for the monitoring of quaternary effluent in a pilot scale plant installed downstream of a water reuse facility.

Can Broadening the Kidney Biopsy Criteria Reduce Misleading Diagnoses in Young Patients with End-Stage Renal Diseases? A Survey on the Sicilian Registry of Nephrology, Dialysis, and Transplantation.

Audits allow analysis of the delivery of care and the prevalence of diseases. This study investigated kidney diseases' impact on end-stage renal disease (ERSD) in patients younger than 30 years. : This analysis is retrospectively conducted on young dialysis-dependent patients included in the Sicilian Registry of Nephrology, Dialysis and Transplantation Participants.

Traditional, alternative, and emerging therapeutics for focal segmental glomerulosclerosis.

Introduction: Segmental focal glomerulosclerosis is a histological lesion characterized by podocyte damage. It may be a primary disease linked to an unknown circulating factor, secondary to viral infections, drug toxicity, or a disadaptive response to the loss of nephrons, or it may depend on gene mutations or have an indeterminate cause. The treatment of the primary form involves immunosuppressors.

Idiopathic inflammatory myopathy and C3 glomerulopathy: a rare association.

Idiopathic inflammatory myopathies represent a spectrum of autoimmune disorders primarily characterized by muscle inflammation. While renal involvement in idiopathic inflammatory myopathies has historically been considered rare, recent findings indicate a prevalence of approximately 21-23%. Renal manifestations in idiopathic inflammatory myopathies are generally secondary to acute renal injury from rhabdomyolysis or, more rarely, occur through autoimmune mechanisms leading to glomerulonephritis.